Adalimumab for the treatment of refractory noninfectious paediatric uveitis

Area of Science:

• Ophthalmology
• Immunology
• Pediatrics

Background:

• Noninfectious uveitis in children can lead to severe vision loss.
• Refractory cases often require advanced therapeutic options.
• Biologic agents are increasingly explored for managing pediatric autoimmune conditions.

Purpose of the Study:

• To evaluate the efficacy and safety of adalimumab (ADA) in treating severe, refractory noninfectious pediatric uveitis.
• To assess the impact of ADA on disease activity and visual acuity.
• To document the types of uveitis and pre-existing structural damage in the study cohort.

Main Methods:

• Retrospective case series of 12 pediatric patients treated with ADA from 2008-2015.
• Patients had various forms of refractory noninfectious uveitis.
• Outcomes assessed using Standardization of Uveitis Nomenclature (SUN) criteria and visual acuity measurements.

Main Results:

• All 12 patients showed improved uveitis activity after initiating ADA therapy.
• Visual acuity improved or remained stable in 17 out of 19 affected eyes.
• ADA exhibited a good safety profile, with no new major adverse events reported related to the drug.

Conclusions:

• Adalimumab (ADA) is an effective treatment for severe refractory noninfectious pediatric uveitis.
• ADA can lead to significant improvement in disease control and visual outcomes.
• The drug is well-tolerated in the pediatric population, offering a valuable therapeutic option.